JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
This product is based on Osmotic Controlled Release Oral Delivery System technology
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
Subscribe To Our Newsletter & Stay Updated